Thursday, September 15, 2016

Aygestin Oral, Implantation, Parenteral


Generic Name: progestin contraceptives (Oral route, Parenteral route)


Commonly used brand name(s)

In the U.S.


  • Aygestin

  • Camila

  • Errin

  • Jolivette

  • Next Choice

  • Nora-BE

  • Nor-QD

  • Ortho Micronor

  • Ovrette

  • Plan B

  • Plan B One-Step

  • Provera

Available Dosage Forms:


  • Tablet

Uses For Aygestin


Progestins are hormones.


The low-dose progestins for contraception are used to prevent pregnancy. Other names for progestin-only oral contraceptives are minipills and progestin-only pills (POPs). Progestins can prevent fertilization by preventing a woman's egg from fully developing.


Also, progestins cause changes at the opening of the uterus, such as thickening of the cervical mucus. This makes it hard for the partner's sperm to reach the egg. The fertilization of the woman's egg with her partner's sperm is less likely to occur while she is taking, receiving, or using a progestin, but it can occur. Even so, the progestins make it harder for the fertilized egg to become attached to the walls of the uterus, making it difficult to become pregnant.


No contraceptive method is 100 percent effective. Studies show that fewer than 1 of each 100 women become pregnant during the first year of use after correctly receiving the injection on time. Fewer than 10 of each 100 women who take progestins correctly by mouth for contraception become pregnant during the first year of use. Methods that do not work as well include condoms, diaphragms, or spermicides. Discuss with your doctor what your options are for birth control.


Progestin contraceptives are available only with your doctor's prescription.


Importance of Diet


Make certain your doctor knows if you are on any special diet, such as a low-sodium or low-sugar diet.


Before Using Aygestin


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to medicines in this group or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Progestins have been used by teenagers and have not been shown to cause different side effects or problems than they do in adults. You must take progestin-only oral contraceptives every day in order for them to work. Progestins do not protect against sexually transmitted diseases, a risk factor for teenagers. It is not known if Depo-Provera Contraceptive Injection causes problems with bone development and growth in teenagers and young women. It is important that your doctor check you regularly for growth problems, especially if you have been using this medicine for 2 years or longer.


Geriatric


This medicine has been tested and has not been shown to cause different side effects or problems in older people than it does in younger adults.


Pregnancy


Use of progestin-only contraceptives during pregnancy is not recommended. Doctors should be told if pregnancy is suspected. When accidently used during pregnancy, progestins used for contraception have not caused problems.


Breast Feeding


Although progestins pass into the breast milk, the low doses of progestins used for contraception have not been shown to cause problems in nursing babies. Progestins used for contraception are recommended for nursing mothers when contraception is desired.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking any of these medicines, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using medicines in this class with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Isotretinoin

  • Theophylline

  • Tizanidine

  • Tranexamic Acid

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of medicines in this class. Make sure you tell your doctor if you have any other medical problems, especially:


  • Asthma or

  • Epilepsy, or history of or

  • Heart or circulation problems or

  • Kidney disease, severe or

  • Migraine headaches—May cause fluid buildup and make these conditions worse.

  • Bleeding problems, undiagnosed, such as blood in the urine or changes in vaginal bleeding—May make diagnosis of these problems more difficult.

  • Breast disease (e.g., breast lumps or cysts), history of—May make this condition worse in certain types of diseases that do not react to progestins in a positive way.

  • Central nervous system (CNS) disorders (e.g., depression), or history of or

  • High blood cholesterol or

  • Osteoporosis (brittle bones), or a family history of—May cause these conditions to occur or make these conditions worse.

  • Diabetes mellitus—May cause a mild increase in blood sugar and a need to monitor blood sugar more often.

  • Liver disease—The effects of some progestins may be increased. May make this condition worse.

Proper Use of progestin contraceptives

This section provides information on the proper use of a number of products that contain progestin contraceptives. It may not be specific to Aygestin. Please read with care.


To make the use of a progestin as safe and reliable as possible, you should understand how and when to take it and what effects may be expected. Progestins for contraception usually come with patient directions. Read them carefully before taking or using this medicine.


Progestins do not protect a woman from sexually transmitted diseases (STDs), including human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS). The use of latex (rubber) condoms or abstinence is recommended for protection from these diseases.


Take this medicine only as directed by your doctor. Do not take more of it and do not take it for a longer time than your doctor ordered. To do so may increase the chance of side effects. Try to take the medicine at the same time each day to reduce the possibility of side effects and to allow it to work better.


When using levonorgestrel tablet dosage form for emergency contraception:


  • The tablets may be taken at any time during the menstrual cycle.

When using medroxyprogesterone injection dosage form for contraception:


  • Your injection is given by a health care professional every 3 months.

  • To stop using medroxyprogesterone injection for contraception, simply do not have another injection.

  • Full protection from pregnancy begins immediately if you receive the first injection within the first 5 days of your menstrual period or within 5 days after delivering a baby if you will not be breast-feeding. If you are going to breast-feed, you may have to wait for 6 weeks from your delivery date before receiving your first injection. If you follow this schedule, you do not need to use another form of birth control. Protection from that one injection ends at 3 months. You will need another injection every 3 months to have full protection from becoming pregnant. However, if the injection is given later than 5 days from the first day of your last menstrual period, you will need to use another method of birth control as directed by your doctor.

When using an oral progestin dosage form:


  • Take a tablet every 24 hours each day of the year. Taking the medicine at the same time each day helps to reduce the possibility of side effects and makes it work as expected. Taking your tablet 3 hours late is the same as missing a dose and can cause the medicine to not work properly.

  • Keep the tablets in the container in which you received them to help you to keep track of your dosage schedule.

  • When switching from estrogen and progestin oral contraceptives, you should take the first dose of the progestin-only contraceptive the next day after the last active pill of the estrogen and progestin oral contraceptive has been taken. This means you will not take the last 7 days (placebo or nonactive pills) of a 28-day cycle of the estrogen and progestin oral contraceptive pack. You will begin a new pack of progestin-only birth control pills on the 22nd day.

  • Also, when switching, full protection from pregnancy begins after 48 hours if the first dose of the progestin-only contraceptive is taken on the first day of the menstrual period. If the birth control is begun on other days, full protection may begin 3 weeks after you begin taking the medicine for the first time. You should use a second method of birth control for at least the first 3 weeks to ensure full protection. You are not fully protected if you miss pills. The chances of your getting pregnant are greater with each pill that is missed.

Follow your doctor's orders to schedule the proper time to receive an injection of progestins for contraception.


Dosing


The dose medicines in this class will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of these medicines. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For levonorgestrel

  • For oral dosage form (tablets):
    • For emergency contraception for preventing pregnancy:
      • Adults and teenagers—The first dose of 0.75 milligram should be taken as soon as possible within 72 hours of intercourse. The second dose must be taken 12 hours later.



  • For medroxyprogesterone

  • For muscular injection dosage form
    • For preventing pregnancy:
      • Adults and teenagers—150 milligrams injected into a muscle in the upper arm or in the buttocks every three months (13 weeks).



  • For subcutaneous injection dosage form
    • For preventing pregnancy:
      • Adults and teenagers—104 milligrams injected under the skin of the anterior thigh or abdomen every three months (12 to 14 weeks).



  • For norethindrone

  • For oral dosage form (tablets):
    • For preventing pregnancy:
      • Adults and teenagers—0.35 milligrams every 24 hours, beginning on the first day of your menstrual cycle whether menstrual bleeding begins or not. The first day of your menstrual cycle can be figured out by counting 28 days from the first day of your last menstrual cycle.



  • For norgestrel

  • For oral dosage form (tablets):
    • For preventing pregnancy:
      • Adults and teenagers—75 micrograms every 24 hours, beginning on the first day of your menstrual cycle whether menstrual bleeding occurs or not. The first day of your menstrual cycle can be figured out by counting 28 days from the first day of your last menstrual cycle.



Missed Dose


Call your doctor or pharmacist for instructions.


For oral dosage form (tablets):


  • When you miss 1 day's dose of oral tablets or are 3 hours or more late in taking your dose, many doctors recommend that you take the missed dose immediately, continue your normal schedule, and use another method of contraception for 2 days. This is different from what is done after a person misses a dose of birth control tablets that contain more than one hormone.

For injection dosage form:


  • If you miss having your next injection and it has been longer than 13 weeks since your last injection, your doctor may want you to stop receiving the medicine. Use another method of birth control until your period begins or until your doctor determines that you are not pregnant.

  • If your doctor has other directions, follow that advice. Any time you miss a menstrual period within 45 days after a missed or delayed dose you will need to be tested for a possible pregnancy.

Storage


Keep out of the reach of children.


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Aygestin


It is very important that your doctor check your progress at regular visits. This will allow your dosage to be adjusted to your changing needs, and will allow any unwanted effects to be detected. These visits are usually every 12 months when you are taking progestins by mouth for birth control.


  • If you are receiving the medroxyprogesterone injection for contraception, a physical exam is needed only every 12 months, but you need an injection every 3 months. Your doctor will also want to check you for any bone development or growth problems, especially if you are a teenager or young adult.

Progestins may cause dizziness in some people. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert.


It is possible that certain doses of progestins may cause a temporary thinning of the bones by changing your hormone balance. It is important that your doctor know if you have an increased risk of osteoporosis. Some things that can increase your risk for osteoporosis include cigarette smoking, abusing alcohol, taking or drinking large amounts of caffeine, and having a family history of osteoporosis or easily broken bones. Some medicines, such as steroids (cortisone-like medicines) or anticonvulsants (seizure medicines), can also cause thinning of the bones. It is especially important that you tell your doctor about any of these risk factors if you are taking Depo-Provera® Contraceptive Injection or Depo-SubQ Provera® 104. These contraceptives may cause a loss of bone mineral density. Your doctor may replace these contraceptives with a different one.


Vaginal bleeding of various amounts may occur between your regular menstrual periods during the first 3 months of use. This is not unusual and does not mean you should stop the medicine. This is sometimes called spotting when the bleeding is slight, or breakthrough bleeding when it is heavier. If this occurs, continue on your regular dosing schedule. Check with your doctor:


  • If vaginal bleeding continues for an unusually long time.

  • If your menstrual period has not started within 45 days of your last period.

Missed menstrual periods may occur. If you suspect a pregnancy, you should call your doctor immediately.


If you are scheduled for any laboratory tests, tell your doctor that you are taking a progestin. Progestins can change certain test results.


The following medicines might reduce the effectiveness of progestins for contraception:


  • Aminoglutethimide (e.g., Cytadren®)

  • Carbamazepine (e.g., Tegretol®)

  • Phenobarbital

  • Phenytoin (e.g., Dilantin®)

  • Rifabutin (e.g., Mycobutin®)

  • Rifampin (e.g., Rifadin®)

Sometimes your doctor may use these medicines with progestins for contraception, but the doctor will give you special directions to follow to make sure your progestin is working properly. In order to prevent pregnancy, use a second method of birth control together with the progestin when you also use a medicine that could reduce the effectiveness of the progestin. If you are using medroxyprogesterone injection for contraception, continue using a back-up method of birth control until you have your next injection, even if the medicine that affects contraceptives is discontinued. If you are using the oral tablets, continue using a back-up method of birth control for a full cycle (or 4 weeks), even if the medicine that affects contraceptives is discontinued.


If you vomit your oral progestin-only contraceptive for any reason within a few hours after taking it, do not take another dose. Return to your regular dosing schedule and use an additional back-up method of birth control for 48 hours.


If you are receiving levonorgestrel tablets for emergency contraception and vomiting occurs within 1 hour after taking either dose of the medicine, contact your physician to discuss whether the dose should be repeated.


Aygestin Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


More common
  • Changes in uterine bleeding (increased amounts of menstrual bleeding occurring at regular monthly periods

  • heavier uterine bleeding between regular monthly periods

  • lighter uterine bleeding between menstrual periods

  • or stopping of menstrual periods

Less common
  • Mental depression

  • skin rash

  • unexpected or increased flow of breast milk

Incidence not known - for patients taking Depo-Provera Contraceptive Injection
  • Cough

  • decrease in height

  • difficulty swallowing

  • fast heartbeat

  • hives, itching, puffiness, or swelling of the eyelids or around the eyes, face, lips or tongue

  • pain in back, ribs, arms, or legs

  • pain or swelling in arms or legs without any injury

  • shortness of breath

  • skin rash

  • tightness in chest

  • wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Abdominal pain or cramping

  • diarrhea

  • dizziness

  • fatigue

  • mild headache

  • mood changes

  • nausea

  • nervousness

  • pain or irritation at the injection site

  • swelling of face, ankles, or feet

  • unusual tiredness or weakness

  • vomiting

  • weight gain

Less common
  • Acne

  • breast pain or tenderness

  • brown spots on exposed skin, possibly long-lasting

  • hot flashes

  • loss or gain of body, facial, or scalp hair

  • loss of sexual desire

  • trouble in sleeping

Not all of the side effects listed above have been reported for each of these medicines, but they have been reported for at least one of them. All of the progestins are similar, so any of the above side effects may occur with any of these medicines.


After you stop using this medicine, your body may need time to adjust. The length of time this takes depends on the amount of medicine you were using and how long you used it. During this period of time, check with your doctor if you notice any of the following side effects:


  • Delayed return to fertility

  • stopping of menstrual periods

  • unusual menstrual bleeding (continuing)

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

Aygestin



norethindrone acetate

Dosage Form: tablet
Aygestin® (norethindrone acetate tablets, USP)

11001631


Iss. 2/2010


Rx only



Aygestin Description


Aygestin® (norethindrone acetate tablets, USP) - 5 mg oral tablets.


Aygestin® (norethindrone acetate tablets, USP), (17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. The structural formula is as follows:



C22H28O3 M.W. 340.46


Aygestin® (norethindrone acetate tablets, USP) contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose.



Aygestin - Clinical Pharmacology


Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone.



Pharmacokinetics


Absorption

Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from Aygestin  tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of Aygestin  in 29 healthy female volunteers are summarized in Table 1.















Table 1


Pharmacokinetic Parameters after a Single Dose of

Aygestin® in Healthy Women
Aygestin® (n = 29) Arithmetic Mean ± SD
Norethindrone (NET)
AUC (0-inf)(ng/ml*h)166.90 ± 56.28
Cmax (ng/ml)26.19 ± 6.19
tmax (h)1.83 ± 0.58
t1/2 (h)8.51 ± 2.19

AUC = area under the curve,


Cmax = maximum plasma concentration,


tmax = time at maximum plasma concentration,


t1/2 = half-life,


SD = standard deviation


Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions



Effect of Food

The effect of food administration on the pharmacokinetics of Aygestin  has not been studied.


Distribution

Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg.


Metabolism

Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.


Excretion

Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of Aygestin  is approximately 9 hours.



Special Populations


Geriatrics

The effect of age on the pharmacokinetics of norethindrone after Aygestin  administration has not been evaluated.


Race

The effect of race on the disposition of norethindrone after Aygestin  administration has not been evaluated.


Renal Insufficiency

The effect of renal disease on the disposition of norethindrone after Aygestin administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function.


Hepatic Insufficiency

The effect of hepatic disease on the disposition of norethindrone after Aygestin  administration has not been evaluated. However, Aygestin  is contraindicated in markedly impaired liver function or liver disease.


Drug Interactions

No pharmacokinetic drug interaction studies investigating any drug-drug interactions with Aygestin  have been conducted.



Indications and Usage for Aygestin


INDICATIONS AND USAGE


Aygestin (norethindrone acetate tablets, USP) is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Aygestin (norethindrone acetate tablets, USP) is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.



Contraindications


  • Known or suspected pregnancy. There is no indication for Aygestin in pregnancy. (See PRECAUTIONS.)

  • Undiagnosed vaginal bleeding

  • Known, suspected or history of cancer of the breast

  • Active deep vein thrombosis, pulmonary embolism or history of these conditions

  • Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)

  • Impaired liver function or liver disease

  • As a diagnostic test for pregnancy

  • Hypersensitivity to any of the drug components


Warnings


  1.    Cardiovascular Disorders

    Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.

  2. Visual Abnormalities

    Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued.


Precautions



General


  • Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation.

  • In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated.

  • Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.

  • Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy.

  • The pathologist should be advised of progestin therapy when relevant specimens are submitted.


Information for Patients


Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe Aygestin.



Drug/Laboratory Tests Interactions


The following laboratory test results may be altered by the use of estrogen/progestin combination drugs:


  1.    Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.

  2.   Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.

  3. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).

  4. Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels.

  5. Impaired glucose metabolism.

  6. Reduced response to metyrapone test.


Carcinogenesis, Mutagenesis, Impairment of Fertility


Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established.



Pregnancy


Category X

Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses.



Nursing Mothers


Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman.



Pediatric Use


Aygestin tablets  are not indicated in children.



Adverse Reactions


See WARNINGS and PRECAUTIONS.


The following adverse reactions have been observed in women taking progestins:


  • Breakthrough bleeding

  • Spotting

  • Change in menstrual flow

  • Amenorrhea

  • Edema

  • Changes in weight (decreases, increases)

  • Changes in the cervical squamo-columnar junction and cervical secretions

  • Cholestatic jaundice

  • Rash (allergic) with and without pruritus

  • Melasma or chloasma

  • Clinical depression

  • Acne

  • Breast enlargement/tenderness

  • Headache/migraine

  • Urticaria

  • Abnormalities of liver tests (i.e., AST, ALT, Bilirubin)

  • Decreased HDL cholesterol and increased LDL/HDL ratio

  • Mood swings

  • Nausea

  • Insomnia

  • Anaphylactic/anaphylactoid reactions

  • Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism)

  • Optic neuritis (which may lead to partial or complete loss of vision)


Aygestin Dosage and Administration


Therapy with Aygestin (norethindrone acetate tablets, USP) must be adapted to the specific indications and therapeutic response of the individual patient.


Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology


2.5 to 10 mg Aygestin (norethindrone acetate tablets, USP) may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen.


Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing Aygestin (norethindrone acetate tablets, USP) therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with Aygestin (norethindrone acetate tablets, USP).



Endometriosis


Initial daily dosage of 5 mg Aygestin (norethindrone acetate tablets, USP) for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of Aygestin (norethindrone acetate tablets, USP) is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination.



How is Aygestin Supplied


Aygestin® (norethindrone acetate tablets, USP) are available as:


5 mg: White, oval, flat-faced, beveled edge tablet scored on one side. Debossed with 5 Aygestin on the unscored side and b / 424 on the scored side. Available in bottles of 50 tablets.


Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).


Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].


KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.


Teva Women’s Health, Inc.

Subsidiary of Teva Pharmaceuticals USA, Inc.

Sellersville, PA 18960


Iss. 2/2010



PATIENT INFORMATION


Rx only


Read this PATIENT INFORMATION before you start taking Aygestin (norethindrone acetate tablets, USP) and read what you get each time you refill Aygestin (norethindrone acetate tablets, USP). There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition.


What is the most important information I should know about Aygestin (norethindrone acetate tablets, USP) (A Progestin Hormone)?


  • Do not use Aygestin (norethindrone acetate tablets, USP) if you are pregnant, breastfeeding or are trying to conceive.

  • Do not use Aygestin (norethindrone acetate tablets, USP) if you have had a previous blood clot, stroke, or heart attack.

  • Do not use Aygestin (norethindrone acetate tablets, USP) if you are postmenopausal.

 What is Aygestin (norethindrone acetate tablets, USP)?


Aygestin (norethindrone acetate tablets, USP)  is similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide Aygestin (norethindrone acetate tablets, USP)  as individual tablets.


What are Aygestin (norethindrone acetate tablets, USP) used for?


Aygestin (norethindrone acetate tablets, USP) are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance.


Who should not take Aygestin (norethindrone acetate tablets, USP)?


You should not take Aygestin (norethindrone acetate tablets, USP)  if you are postmenopausal, pregnant or breastfeeding.


You should not take Aygestin (norethindrone acetate tablets, USP) if you have the following conditions:


  • Known or suspected pregnancy. Aygestin (norethindrone acetate tablets, USP) are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take Aygestin (norethindrone acetate tablets, USP) during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take Aygestin (norethindrone acetate tablets, USP)  and later find out you were pregnant, talk with your healthcare provider right away.

  • History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions

  • Liver impairment or disease

  • Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take Aygestin (norethindrone acetate tablets, USP).

  • Undiagnosed vaginal bleeding

  • Hypersensitivity to Aygestin (norethindrone acetate tablets, USP). See the end of this leaflet for a list of all of the ingredients in Aygestin (norethindrone acetate tablets, USP).

What are the risks associated with Aygestin (norethindrone acetate tablets, USP)?


  • Risk to the Fetus

Aygestin (norethindrone acetate tablets, USP) should not be used if you are pregnant. Aygestin (norethindrone acetate tablets, USP) are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy.


You should avoid using Aygestin (norethindrone acetate tablets, USP) during pregnancy. If you take Aygestin (norethindrone acetate tablets, USP)  and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible.


  • Abnormal Blood Clotting

Use of progestational drugs, such as Aygestin (norethindrone acetate tablets, USP), has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug.


  • Eye Abnormalities

Discontinue Aygestin (norethindrone acetate tablets, USP)  tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine.


These are some of the warning signs of serious side effects with progestin therapy


  • Breast lumps

  • Dizziness and faintness

  • Changes in speech

  • Severe headaches

  • Chest pain

  • Shortness of breath

  • Pains in your legs

  • Changes in vision

 Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.


Common side effects include


  • Headache

  • Breast pain

  • Irregular vaginal bleeding or spotting

  • Stomach/abdominal cramps/bloating

  • Nausea and vomiting

  • Hair loss

 Other side effects include


  • High blood pressure

  • Liver problems

  • High blood sugar

  • Fluid retention

  • Enlargements of benign tumors of the uterus (“fibroids”)

  • Vaginal yeast infections

  • Mental depression

These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist.


What can I do to lower my chances of getting a serious side effect with

Aygestin (norethindrone acetate tablets, USP)  ?


  • Talk with your healthcare provider regularly about whether you should continue taking Aygestin (norethindrone acetate tablets, USP).

  • Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.

  • If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks.

General information about the safe and effective use of Aygestin (norethindrone acetate tablets, USP)


Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take Aygestin (norethindrone acetate tablets, USP)  for conditions for which it was not prescribed. Do not give Aygestin (norethindrone acetate tablets, USP)  tablets  to other people, even if they have the same symptoms you have. It may harm them.


Keep Aygestin (norethindrone acetate tablets, USP)  out of the reach of children.


This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about Aygestin (norethindrone acetate tablets, USP)  that is written for health professionals.


What are the ingredients in Aygestin (norethindrone acetate tablets, USP) ?


Aygestin (norethindrone acetate tablets, USP)  contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose.


Teva Women’s Health, Inc.

Subsidiary of Teva Pharmaceuticals USA, Inc.

Sellersville, PA 18960


Iss. 2/2010



PRINCIPAL DISPLAY PANEL




Aygestin® (norethindrone acetate tablets, USP) 5 mg 50 Tablets Label Text


NDC 51285-424-10


Aygestin®


(norethindrone acetate


tablets, USP)


ORALLY ACTIVE PROGESTIN


5 mg


PHARMACIST: Dispense the accompanying


PATIENT INFORMATION leaflet to each patient.


Rx only


TEVA


TEVA WOMAN'S HEALTH


50 TABLETS









Aygestin 
norethindrone acetate  tablet










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)51285-424
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
NORETHINDRONE ACETATE (NORETHINDRONE)NORETHINDRONE ACETATE5 mg










Inactive Ingredients
Ingredient NameStrength
ANHYDROUS LACTOSE 
MAGNESIUM STEARATE 
CELLULOSE, MICROCRYSTALLINE 


















Product Characteristics
ColorWHITEScore2 pieces
ShapeOVALSize11mm
FlavorImprint Code5;Aygestin;b;424
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
151285-424-1050 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07595105/25/2001


Labeler - Teva Women's Health, Inc. (017038951)
Revised: 07/2011Teva Women's Health, Inc.

More Aygestin resources


  • Aygestin Side Effects (in more detail)
  • Aygestin Dosage
  • Aygestin Use in Pregnancy & Breastfeeding
  • Drug Images
  • Aygestin Drug Interactions
  • Aygestin Support Group
  • 3 Reviews for Aygestin - Add your own review/rating


  • Aygestin Concise Consumer Information (Cerner Multum)

  • Aygestin Monograph (AHFS DI)

  • Aygestin Oral, Implantation, Parenteral Advanced Consumer (Micromedex) - Includes Dosage Information

  • Aygestin MedFacts Consumer Leaflet (Wolters Kluwer)

  • Nor-QD MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Aygestin with other medications


  • Abnormal Uterine Bleeding
  • Amenorrhea
  • Endometriosis

Adipex-P



Generic Name: phentermine (FEN ter meen)

Brand Names: Adipex-P, Oby-Cap, T-Diet, Zantryl


What is Adipex-P (phentermine)?

Phentermine is a stimulant that is similar to an amphetamine. Phentermine is an appetite suppressant that affects the central nervous system.


Phentermine is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol, or diabetes.


Phentermine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Adipex-P (phentermine)?


Do not use phentermine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects. Taking phentermine together with other diet medications such as fenfluramine (Phen-Fen) or dexfenfluramine (Redux) can cause a rare fatal lung disorder called pulmonary hypertension. Do not take phentermine with any other diet medications without your doctor's advice. Phentermine may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of phentermine.

Phentermine is only part of a complete program of treatment that may also include diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.


Phentermine may be habit-forming and should be used only by the person it was prescribed for. Never share phentermine with another person, especially someone with a history of drug abuse or addiction. Keep track of the amount of medicine used from each new bottle. Phentermine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription. Do not stop using phentermine suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using phentermine.

What should I discuss with my healthcare provider before taking Adipex-P (phentermine)?


Do not use phentermine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Taking phentermine together with other diet medications such as fenfluramine (Phen-Fen) or dexfenfluramine (Redux) can cause a rare fatal lung disorder called pulmonary hypertension. Do not take phentermine with any other diet medications without your doctor's advice.


You should not take phentermine if you are allergic to it, or if you have:

  • coronary artery disease (hardening of the arteries);




  • heart disease;




  • severe or uncontrolled high blood pressure;




  • overactive thyroid;




  • glaucoma;




  • if you have a history of drug or alcohol abuse; or




  • if you are allergic to other diet pills, amphetamines, stimulants, or cold medications.



To make sure you can safely take phentermine, tell your doctor if you have any of these other conditions:



  • high blood pressure;




  • diabetes; or




  • a thyroid disorder.




FDA pregnancy category C. It is not known whether phentermine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Phentermine can pass into breast milk and may harm a nursing baby. You should not breast-feed while taking phentermine. Do not give this medication to a child younger than 16 years old. Phentermine may be habit-forming and should be used only by the person it was prescribed for. Never share phentermine with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it.

How should I take Adipex-P (phentermine)?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


It is best to take phentermine on an empty stomach before breakfast or within 2 hours after breakfast.

To prevent sleep problems, take this medication early in the day, no later than 6:00 pm.


Talk with your doctor if you have increased hunger or if you otherwise think the medication is not working properly. Taking more of this medication will not make it more effective and can cause serious, life-threatening side effects.

Phentermine should be taken only for a short time, such as a few weeks.


Do not stop taking phentermine suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using phentermine. Store at room temperature away from moisture and heat. Keep track of the amount of medicine used from each new bottle. Phentermine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.

See also: Adipex-P dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of phentermine can be fatal.

Overdose symptoms may include confusion, hallucinations, panic, feeling hostile or aggressive, nausea, vomiting, diarrhea, stomach cramps, irregular heartbeat, rapid breathing, overactive reflexes, confusion, hallucinations, seizure (convulsions), feeling light-headed, or fainting.


What should I avoid while taking Adipex-P (phentermine)?


Drinking alcohol can increase certain side effects of phentermine. Phentermine may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Adipex-P (phentermine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

  • feeling short of breath, even with mild exertion;




  • chest pain, feeling like you might pass out;




  • swelling in your ankles or feet;




  • pounding heartbeats or fluttering in your chest;




  • confusion or irritability, unusual thoughts or behavior;




  • feelings of extreme happiness or sadness; or




  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).



Less serious side effects may include:



  • feeling restless or hyperactive;




  • headache, dizziness, tremors;




  • sleep problems (insomnia);




  • dry mouth or an unpleasant taste in your mouth;




  • diarrhea or constipation, upset stomach; or




  • increased or decreased interest in sex, impotence.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Adipex-P (phentermine)?


Tell your doctor about all other medicines you use, especially:



  • blood pressure medications;




  • insulin or oral diabetes medication; or




  • an antidepressant such as citalopram (Celexa), fluoxetine (Prozac, Sarafem, Symbyax), paroxetine (Paxil), sertraline (Zoloft), and others.



This list is not complete and other drugs may interact with phentermine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Adipex-P resources


  • Adipex-P Side Effects (in more detail)
  • Adipex-P Dosage
  • Adipex-P Use in Pregnancy & Breastfeeding
  • Drug Images
  • Adipex-P Drug Interactions
  • Adipex-P Support Group
  • 145 Reviews for Adipex-P - Add your own review/rating


  • Adipex-P MedFacts Consumer Leaflet (Wolters Kluwer)

  • Adipex-P Prescribing Information (FDA)

  • Phentermine Prescribing Information (FDA)

  • Phentermine Monograph (AHFS DI)

  • Fastin Advanced Consumer (Micromedex) - Includes Dosage Information

  • Ionamin MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ionamin Prescribing Information (FDA)



Compare Adipex-P with other medications


  • Obesity
  • Weight Loss


Where can I get more information?


  • Your pharmacist can provide more information about phentermine.

See also: Adipex-P side effects (in more detail)


Asparaginase


Class: Antineoplastic Agents
VA Class: AN900
CAS Number: 9015-68-3
Brands: Elspar

Introduction

Antineoplastic agent; enzyme derived from Escherichia coli.108 a


Uses for Asparaginase


Acute Lymphocytic Leukemia (ALL)


Component of combination chemotherapeutic regimens for the treatment of ALL.107 108 109 110 111 112 114 122 123 124 Used in induction and/or intensification (consolidation) regimens.109 110 122 123 124


In non-high-risk childhood ALL, combination therapy with asparaginase (or pegaspargase), a corticosteroid (dexamethasone or prednisone), and vincristine is used as an induction regimen.109 Intensive induction regimens with ≥4 drugs, including asparaginase (or pegaspargase), an anthracycline (e.g., daunorubicin), a corticosteroid, and vincristine, with or without cyclophosphamide, may improve event-free survival but cause greater toxicity.107 109 111 Some clinicians reserve 4-drug regimens for patients with high-risk childhood ALL;107 109 111 others elect to use such regimens for all patients with childhood ALL regardless of presenting features.109


In adults, induction regimens typically include an anthracycline, vincristine, and prednisone; some regimens also add other drugs (e.g., asparaginase, cyclophosphamide).110 122 123


Acute Myeloid Leukemia (AML)


Used in conjunction with high-dose cytarabine as post-induction intensification therapy for AML in patients without a suitable donor for allogeneic bone marrow transplant.117 118


Non-Hodgkin’s Lymphoma


Used in combination with other antineoplastic agents for treatment of non-Hodgkin’s lymphoma (e.g., lymphoblastic lymphoma).107 110 120


Asparaginase Dosage and Administration


General


Hypersensitivity Reactions



  • Monitor patients for hypersensitivity reactions for 1 hour after administration of asparaginase; be prepared to provide immediate treatment.108 (See Sensitivity Reactions under Cautions.)



Administration


Administer by IM injection, IV infusion, or sub-Q injection.108 123 126 130


Discard solutions that appear cloudy, discolored, or contain precipitates.108


Vials are for single use only; discard any unused portion.108


Avoid vigorous shaking; may cause foaming and difficulty removing entire contents of vial.121


IM Administration


Administer by IM injection.108


Do not give >2 mL at one injection site.108


Reconstitution

For IM injection, add 2 mL of 0.9% sodium chloride injection to a vial containing 10,000 units of asparaginase to provide a solution containing 5000 units/mL.108


IV Administration


For solution compatibility information, see Compatibility under Stability.


Administer by IV infusion.108


Filter gelatinous fiber-like particles that develop in standing solutions through a 5-mcm filter during administration.108


Reconstitution

Add 5 mL of 0.9% sodium chloride injection or sterile water to a vial containing 10,000 units of asparaginase to provide a solution containing 2000 units/mL.108


Dilution

For IV infusion, dilute dose in either 0.9% sodium chloride or 5% dextrose injection.121


Rate of Administration

Administer dose slowly (over ≥30 minutes) into the tubing of a freely flowing IV solution.108


Dosage


Dosage expressed in terms of international units (IU, units).108


Consult published protocols for optimum dosage and administration sequence of drugs in combination regimens.a


Pediatric Patients


ALL

Discontinue if pancreatitis, serious allergic reaction, or serious thrombotic reaction occurs.108


Induction Therapy

IM or IV

Manufacturer recommends 6000 units/m2 3 times a week.108


Adults


ALL

Discontinue if pancreatitis, serious allergic reaction, or serious thrombotic reaction occurs.108


Induction Therapy

IM

Manufacturer recommends 6000 units/m2 3 times a week.108


Linker regimen: 6000 units/m2 daily on days 17–28 (total of 12 doses) during 4-week induction phase.122


IV

Manufacturer recommends 6000 units/m2 3 times a week.108


Sub-Q

Larson regimen: 6000 units/m2 for 6 doses (days 5, 8, 11, 15, 18, and 22) during 4-week induction phase.123


Intensification (Consolidation) Phase

IM

Linker regimen: 12,000 units/m2 for 6 doses (days 2, 4, 7, 9, 11, and 14) during cycles 1, 3, 5, and 7 (of a total of 9 cycles administered approximately monthly).122


Sub-Q

Larson regimen: 6000 units/m2 for 4 doses (days 15, 18, 22, and 25) during each of two 4-week early intensification periods.123


Special Populations


No special population dosage recommendations at this time.108


Cautions for Asparaginase


Contraindications



  • History of serious thrombosis associated with prior asparaginase therapy.108




  • History of pancreatitis with prior asparaginase therapy.108 (See Pancreatitis under Cautions.)




  • History of serious hemorrhagic events associated with prior asparaginase therapy.108




  • History of serious allergic reactions to asparaginase derived from E. coli.108



Warnings/Precautions


Sensitivity Reactions


Hypersensitivity

Potential for severe sensitivity reactions (e.g., anaphylaxis).108 116 117 126 129 Risk of hypersensitivity reactions increases upon reexposure to the drug;108 a more common with IV than with IM administration.116 125 126


If severe hypersensitivity reaction occurs, discontinue immediately and institute appropriate therapy as indicated (e.g., antihistamine, epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).108


Intradermal sensitivity testing has limited value in predicting hypersensitivity; false-positive and false-negative results occur.126


Thrombotic Effects


Thrombotic events (e.g., sagittal sinus thrombosis,101 108 cerebral infarction,101 thrombosis associated with a central venous catheter,122 superficial and deep-vein thrombosis,101 123 130 132 pulmonary embolism123 130 ) have been reported;108 discontinue the drug in patients with serious thrombotic events.108


Coagulopathy


Coagulopathy (e.g., prolonged PT and PTT; decreased fibrinogen, protein C, protein S, and antithrombin III), sometimes severe,108 a and CNS hemorrhage reported.100 101 102 108 121 Alterations in coagulation factors may predispose individuals to bleeding and/or thrombosis.100 101 102 103 108


Perform coagulation tests (e.g., PT, PTT, fibrinogen) at baseline and periodically during and following therapy.108 In patients with severe or symptomatic coagulopathy, initiate treatment with fresh frozen plasma to replace coagulation factors.108


Pancreatitis


Pancreatitis (sometimes fulminant and fatal) reported.108 a


Evaluate patients with abdominal pain for pancreatitis; discontinue the drug in patients with pancreatitis.108


Hyperglycemia


Glucose intolerance, sometimes irreversible, reported.108


Possible hyperglycemia;108 133 monitor blood glucose concentrations.108


Hepatic Effects


Hepatotoxicity (including hepatic failure), liver disorder, and various liver function abnormalities (e.g., elevated AST, ALT, alkaline phosphatase, and bilirubin [direct and indirect]; decreased albumin and fibrinogen) reported;108 a may be fatal in some patients.a Fatty changes in liver documented on biopsy or autopsy.108 a


Hyperbilirubinemia and elevated ALT and AST occur frequently.108 Marked hypoalbuminemia with peripheral edema may occur.108 a


Hepatic abnormalities usually reversible on discontinuance of therapy;108 some reversal may occur with continued therapy.108


Adequate Patient Monitoring


Perform coagulation tests (e.g., fibrinogen concentrations, PT, PTT) at baseline and periodically during and following therapy.108


Monitor serum glucose concentrations.108


Renal Effects


Azotemia, usually prerenal, occurs frequently.108 a


Discontinue at first sign of renal failure.a


Immunologic Effects


Antibodies to asparaginase may develop.108 Antibody-positive patients more likely to experience a hypersensitivity reaction.108 Hypersensitivity reactions associated with increased clearance of asparaginase.108 (See Sensitivity Reactions under Cautions.)


Clinical implications of antibody formation not fully established, but higher levels of antibody associated with decreased asparaginase activity.108 129 In several studies, development of a hypersensitivity reaction did not appear to alter outcome of treatment for ALL; most patients who required discontinuance of the drug were switched to another formulation (Erwinia-derived asparaginase) to complete treatment.129 130


Specific Populations


Pregnancy

Category C.108


Lactation

Not known whether asparaginase is distributed into milk; discontinue nursing or the drug.108


Pediatric Use

Efficacy of combination chemotherapeutic regimens containing asparaginase established in pediatric patients with ALL.108 109


Adult Use

Toxicity of asparaginase generally is greater in adults than in children.116 117 122 a


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger patients.108


Common Adverse Effects


Allergic reactions,108 116 117 126 129 azotemia,108 a pancreatitis,105 106 108 116 a coagulopathy,108 a hyperglycemia,108 133 CNS thrombosis,101 108 liver function abnormalities (e.g., hyperbilirubinemia, elevated transaminases).108 a


Interactions for Asparaginase


No formal drug interaction studies to date.108


Specific Drugs and Laboratory Tests


















Drug or Test



Interaction



Comments



Methotrexate



Possible decreased effectiveness of methotrexate during period of asparagine suppressiona



Prednisone



Possible increased hyperglycemia133 a



Tests for thyroid function



Decreased serum concentration of thyroxine-binding globulin104



Values return to pretreatment levels within 4 weeks of asparaginase discontinuance104



Vincristine



Possible reduction in hepatic clearance of vincristine135 a


Cumulative neuropathy136 a and disturbances of erythropoiesis if asparaginase and vincristine administered concomitantlya



Manufacturer of vincristine recommends administration of asparaginase 12–24 hours after vincristine135


Consult published protocols for sequence of administration of chemotherapeutic agents in combination regimensa


Asparaginase Pharmacokinetics


Absorption


Bioavailability


Not absorbed from GI tract after oral administration; must be given parenterally.a


Peak plasma concentration attained 14–24 hours after IM administration.108


Distribution


Extent


Following IV administration, apparent volume of distribution is slightly higher than plasma volume.108


Not known whether asparaginase is distributed into milk.108


Crosses blood-brain barrier to a minimal extent.108


Elimination


Half-life


8–30 hours after IV administration.108 a


34–49 hours after IM administration.108


Stability


Storage


Parenteral


Powder for Injection

2–8°C.108


Store reconstituted solutions and solutions diluted for IV infusion at 2–8°C; discard after 8 hours or sooner if solution becomes cloudy.108 121


Compatibility


For information on systemic interactions resulting from concomitant use, see Interactions.


Parenteral


Solution CompatibilityHID






Compatible



Ringer, injection, lactated



Dextrose lcx2 5% in water



Sodium chloride 0.9%


Drug Compatibility





Y-Site CompatibilityHID

Compatible



Methotrexate sodium



Sodium bicarbonate


ActionsActions



  • Inactivates the amino acid asparagine, which is required by tumor cells to synthesize DNA and essential proteins.108 a




  • Resistance to cytotoxic effects of asparaginase develops rapidly.a




  • No apparent cross-resistance between asparaginase and other available antineoplastic agents.a




  • Large foreign protein; therefore, is antigenic and may cause antibody production and varying degrees of hypersensitivity.108 a



Advice to Patients



  • Risk of hypersensitivity reactions, including the possibility of anaphylaxis; importance of patients being monitored for 1 hour after asparaginase administration.108




  • Importance of immediately notifying a clinician if facial swelling, seizures, severe headache, arm or leg swelling, acute shortness of breath, chest pain, or severe abdominal pain occurs.108




  • Importance of immediately notifying a clinician of signs of glucose intolerance (e.g., increased volume or frequency of urination, excessive thirst).108




  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.108




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.108




  • Importance of informing patients of other important precautionary information.108 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Asparaginase

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Parenteral



For injection



10,000 units



Elspar



Lundbeck



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions December 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



100. Cairo MS, Lazarus K, Gilmore RL et al. Intracranial hemorrhage and focal seizures secondary to use of l-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr. 1980; 97:829-33. [IDIS 127909] [PubMed 6933231]



101. Priest JR, Ramsay NKC, Steinherz PG et al. A syndrome of thrombosis and hemorrhage complicating l-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982; 100:984-9. [IDIS 157208] [PubMed 6953221]



102. Lederman GS. Stroke due to treatment with l-asparaginase in an adult. N Engl J Med. 1982; 307:1643. [IDIS 161589] [PubMed 7144855]



103. Priest JR, Ramsay NKC, Bennett AJ et al. The effect of l-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982; 100:990-5. [IDIS 157209] [PubMed 6953222]



104. Garnick MB, Larsen PR. Acute deficiency of thyroxine-binding globulin during l-asparaginase therapy. N Engl J Med. 1979; 301:252-3. [PubMed 109764]



105. Underwood TW, Frye CB. Drug-induced pancreatitis. Clin Pharm. 1993; 12:440-8. [IDIS 314327] [PubMed 8403815]



106. Mclean R, Martin S, Lan-Po-Tang PRL. Fatal case of l-asparaginase induced pancreatitis. Lancet. 1982; 2:1401-2.



107. Anon. Drugs of choice for cancer. Treat Guidel Med Lett. 2003; 1:41-52.



108. Lundbeck Inc. Elspar (asparaginase) prescribing information. Deerfield, IL; 2010 Feb.



109. Childhood acute lymphoblastic leukemia. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2010 Feb 12.



110. Adult acute lymphoblastic leukemia. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2009 Sep 10.



111. Poplack DG, Magrath IT, Kun LE et al. Leukemias and lymphomas of childhood. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott; 1993:1792-1818.



112. Preti A, Kantarjian HM. Management of adult acute lymphocytic leukemia: present issues and key challenges. J Clin Oncol. 1994; 12:1312-22. [IDIS 331854] [PubMed 8201394]



113. Enzon. Oncaspar (pegaspargase) intravenous or intramuscular injection prescribing information. Bridgewater, NJ; 2006 Sep.



114. Keating MJ, Estey E, Kantarjian H. Acute leukemia. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott; 1993:1938-64.



115. Kurtzberg J. A new look at PEG-L-asparaginase and other asparaginases in hematological malignancies. Cancer Invest. 1994; 12(Suppl 1):59.



116. Capizzi RL, Holcenberg JS. Asparaginase. In: Holland JF, Frei E, Bast RC Jr et al, eds. Cancer medicine. 3rd ed. Philadelphia: Lea & Febiger; 1993:796-805.



117. Childhood acute myeloid leukemia/other myeloid malignancies. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 Aug 18.



118. Wells RJ, Woods WG, Lampkin BC et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol. 1993; 11:538-45. [PubMed 8445429]



119. Fragasso G, Pastore MR, Vicari A et al. Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Am J Hematol. 1995; 48:136-7. [PubMed 7847336]



120. Childhood non-Hodgkin lymphoma. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2008 Sep 9.



121. Ovation Pharmaceuticals. Elspar (asparaginase) prescribing information. Deerfield, IL; 2005 Dec.



122. Linker CA, Levitt LJ, O'Donnell M et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991; 78:2814-22. [PubMed 1835410]



123. Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995; 85:2025-37. [PubMed 7718875]



124. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006; 354:166-78. [PubMed 16407512]



125. Nesbit M, Chard R, Evans A et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979; 1:9-13. [PubMed 295576]



126. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009; 102:179-87. [PubMed 19354063]



127. Ohnuma T, Holland JF, Freeman A et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 1970; 30:2297-305. [PubMed 4920133]



128. Evans WE, Tsiatis A, Rivera G et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982; 49:1378-83. [PubMed 7037164]



129. Woo MH, Hak LJ, Storm MC et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000; 18:1525-32. [PubMed 10735901]



130. Larson RA, Fretzin MH, Dodge RK et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998; 12:660-5. [PubMed 9593262]



131. Caruso V, Iacoviello L, Di Castelnuovo A et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006; 108:2216-22. [PubMed 16804111]



132. Caruso V, Iacoviello L, Di Castelnuovo A et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007; 5:621-3. [PubMed 17229043]



133. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 52:814-8. [PubMed 19260096]



134. Sarris A, Cortes J, Kantarjian H et al. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996; 21:85-92. [PubMed 8907274]



135. Hospira Inc. Vincristine sulfate (for injection) prescribing information. Lake Forest, IL; 2007 Dec.



136. Hildebrand J, Kenis Y, Mubashir BA et al. Vincristine neurotoxicity. N Engl J Med. 1972; 287:517.



137. EUSA Pharma (Europe). Products: Erwinase. Available from website. Accessed 2010 May 5.



a. AHFS drug information 2009. McEvoy GK, ed. Asparaginase. Bethesda, MD: American Society of Health-System Pharmacists; 2009: 935–8.



HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:176-7.



More Asparaginase resources


  • Asparaginase Use in Pregnancy & Breastfeeding
  • Asparaginase Drug Interactions
  • Asparaginase Support Group
  • 0 Reviews for Asparaginase - Add your own review/rating


Compare Asparaginase with other medications


  • Acute Lymphocytic Leukemia